Clinical Significance of Plasma and Peripheral Blood Mononuclear Cell EBV-DNA in Lymphoma

IF 2.9 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Journal of Clinical Laboratory Analysis Pub Date : 2025-08-13 DOI:10.1002/jcla.70092

Lu wang, Guobing Xu, Jianjun Xu, Qingyun Zhang

{"title":"Clinical Significance of Plasma and Peripheral Blood Mononuclear Cell EBV-DNA in Lymphoma","authors":"Lu wang, Guobing Xu, Jianjun Xu, Qingyun Zhang","doi":"10.1002/jcla.70092","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Epstein Barr virus (EBV) is a ubiquitous virus that establishes latent infection in the host and plays a critical role in the development and prognosis of lymphomas. The presence of EBV-DNA in peripheral blood is a widely used tumor marker. However, there is no consensus on the preferred blood compartment for EBV-DNA testing.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We retrospectively analyzed data from 256 lymphoma patients, including 21 with Hodgkin lymphoma, 96 with B-cell lymphoma, and 139 with T-cell or NK/T-cell lymphoma. Complete matched PBMC and plasma EBV-DNA datasets were available, allowing correlation analysis and assessment of their respective clinical significance.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Detectable pretreatment EBV-DNA in either plasma or PBMCs was significantly associated with worse survival outcomes (<i>p</i> < 0.001), with the worst prognosis observed in patients positive in both compartments. Longitudinal monitoring demonstrated that patients with negative EBV-DNA or declining viral loads in PBMCs or plasma had significantly improved progression-free survival compared to those with persistent positivity or increasing copy numbers (<i>p</i> < 0.001). Notably, changes in plasma EBV-DNA levels showed higher accuracy than PBMC EBV-DNA in reflecting treatment response. Multivariate analysis identified PBMC EBV-DNA positivity as an independent prognostic factor for inferior OS (<i>p</i> = 0.031) and PFS (<i>p</i> = 0.003).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Both plasma and PBMC EBV-DNA are valuable for prognostic evaluation in lymphoma patients. Plasma EBV-DNA demonstrates superior utility for monitoring treatment response, whereas PBMC EBV-DNA provides stronger prognostic information. Selection of the appropriate sample type should be tailored to the clinical context.</p>\n </section>\n </div>","PeriodicalId":15509,"journal":{"name":"Journal of Clinical Laboratory Analysis","volume":"39 18","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcla.70092","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Laboratory Analysis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcla.70092","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Epstein Barr virus (EBV) is a ubiquitous virus that establishes latent infection in the host and plays a critical role in the development and prognosis of lymphomas. The presence of EBV-DNA in peripheral blood is a widely used tumor marker. However, there is no consensus on the preferred blood compartment for EBV-DNA testing.

Methods

We retrospectively analyzed data from 256 lymphoma patients, including 21 with Hodgkin lymphoma, 96 with B-cell lymphoma, and 139 with T-cell or NK/T-cell lymphoma. Complete matched PBMC and plasma EBV-DNA datasets were available, allowing correlation analysis and assessment of their respective clinical significance.

Results

Detectable pretreatment EBV-DNA in either plasma or PBMCs was significantly associated with worse survival outcomes (p < 0.001), with the worst prognosis observed in patients positive in both compartments. Longitudinal monitoring demonstrated that patients with negative EBV-DNA or declining viral loads in PBMCs or plasma had significantly improved progression-free survival compared to those with persistent positivity or increasing copy numbers (p < 0.001). Notably, changes in plasma EBV-DNA levels showed higher accuracy than PBMC EBV-DNA in reflecting treatment response. Multivariate analysis identified PBMC EBV-DNA positivity as an independent prognostic factor for inferior OS (p = 0.031) and PFS (p = 0.003).

Conclusion

Both plasma and PBMC EBV-DNA are valuable for prognostic evaluation in lymphoma patients. Plasma EBV-DNA demonstrates superior utility for monitoring treatment response, whereas PBMC EBV-DNA provides stronger prognostic information. Selection of the appropriate sample type should be tailored to the clinical context.

Abstract Image

查看原文本刊更多论文

血浆和外周血单个核细胞EBV-DNA在淋巴瘤中的临床意义。

背景：eb病毒（Epstein Barr virus， EBV）是一种普遍存在的病毒，可在宿主中建立潜伏感染，在淋巴瘤的发展和预后中起关键作用。EBV-DNA在外周血中的存在是一种广泛使用的肿瘤标志物。然而，对于EBV-DNA检测的首选血室尚未达成共识。方法：我们回顾性分析了256例淋巴瘤患者的资料，其中21例为霍奇金淋巴瘤，96例为b细胞淋巴瘤，139例为t细胞或NK/ t细胞淋巴瘤。完整匹配的PBMC和血浆EBV-DNA数据集可用，允许相关性分析和评估各自的临床意义。结果：血浆或PBMC中可检测到的EBV-DNA预处理与较差的生存结果显著相关(p)。结论：血浆和PBMC中EBV-DNA对淋巴瘤患者的预后评估都有价值。血浆EBV-DNA在监测治疗反应方面显示出优越的效用，而PBMC EBV-DNA提供了更强的预后信息。应根据临床情况选择合适的样本类型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Laboratory Analysis 医学-医学实验技术

CiteScore

5.60

自引率

7.40%

发文量

584

审稿时长

6-12 weeks

期刊介绍： Journal of Clinical Laboratory Analysis publishes original articles on newly developing modes of technology and laboratory assays, with emphasis on their application in current and future clinical laboratory testing. This includes reports from the following fields: immunochemistry and toxicology, hematology and hematopathology, immunopathology, molecular diagnostics, microbiology, genetic testing, immunohematology, and clinical chemistry.